A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis

Multiple Sclerosis Journal

Volumn 21, Issue 3, 2015, Pages 318-331

  Marrie, Ruth Ann ^a   Reider, Nadia ^a   Cohen, Jeffrey ^b   Stuve, Olaf ^c   Trojano, Maria ^d   Cutter, Gary ^e   Reingold, Stephen ^f   Sorensen, Per Soelberg ^g  

^a UNIVERSITY OF MANITOBA   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BARI   (Italy)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Scientific and Clinical Review Associates LLC   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cardiac; comorbidity; incidence; Multiple sclerosis; peripheral vascular disease; prevalence; stroke; systematic review

Indexed keywords

CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MITRAL VALVE DISEASE; MULTIPLE SCLEROSIS; PERIPHERAL VASCULAR DISEASE; PREDICTIVE VALUE; PREVALENCE; REVIEW; SYSTEMATIC REVIEW; AGE; COMORBIDITY; DISEASE PREDISPOSITION; QUANTITATIVE ANALYSIS; CEREBROVASCULAR DISORDERS; HEART DISEASES; PERIPHERAL VASCULAR DISEASES;

CEREBROVASCULAR DISORDERS; COMORBIDITY; HEART DISEASES; HUMANS; INCIDENCE; MULTIPLE SCLEROSIS; PERIPHERAL VASCULAR DISEASES; PREVALENCE;

EID: 84924762891     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514564485     Document Type: Review

References (68)

1. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: A systematic review. Arch Neurol. 2006 ; 63: 1686-1691
2. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 ; 74: 1041-1047
3. Weinstock-Guttman B, Zivadinov R, Horakova D, et al. Lipid profiles are associated with lesion formation over 24 months in interferon- treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry. 2013 ; 84: 1186-1191
4. Warren SA, Turpin KV, Pohar SL, et al. Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care. 2009 ; 11: 6-16
5. Christiansen CF, Christensen S, Farkas DK, et al. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: A population-based cohort study. Neuroepidemiology. 2010 ; 35: 267-274
6. Fleming ST. Multiple sclerosis as a comorbidity: A study of resource utilization and outcomes of care. Clin Perform Qual Health Care. 1995 ; 3: 23-30
7. Allen NB, Lichtman JH, Cohen HW, et al. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology. 2008 ; 30: 234-238
8. Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple sclerosis: A population-based controlled study. Eur J Neurol. 2010 ; 17: 1215-1219
9. Khan F, Pallant J, Brand C. Caregiver strain and factors associated with caregiver self-efficacy and quality of life in a community cohort with multiple sclerosis. Disabil Rehabil. 2007 ; 29: 1241-1250
10. Lavela SL, Prohaska TR, Furner S, et al. Chronic diseases in male veterans with multiple sclerosis. Prev Chronic Dis. 2012 ; 9: E55
11. Fleming ST, Blake RL. Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol. 1994 ; 47: 1127-1132
12. Marrie R, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview.. 2015 ; 21 (3). 263-281
13. Neyeloff J, Fuchs S, Moreira L. Meta-analyses and Forest plots using a Microsoft Excel spreadsheet: Step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012 ; 5: 52
14. Cox DR. The continuity correction. Biometrika. 1970 ; 57: 217-219
15. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: A descriptive study. Lancet Neurol. 2006 ; 5: 924-931
16. Buchanan RJ, Schiffer R, Stuifbergen A, et al. Demographic and disease characteristics of people with multiple sclerosis living in urban and rural areas. Int J MS Care. 2006 ; 8: 89-98
17. Dallmeijer AJ, Beckerman H, de Groot V, et al. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med. 2009 ; 41: 322-326
18. De Keyser J. Autoimmunity in multiple sclerosis. Neurology. 1988 ; 38: 371-374
19. Deretzi G, Kountouras J, Koutlas E, et al. Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Mult Scler. 2010 ; 16: 1091-1101
20. Eaton WW, Rose NR, Kalaydjian A, et al. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007 ; 29: 1-9
21. Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler. 2004 ; 10: 575-581
22. Finlayson M, Preissner K, Cho C. Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis. Int J MS Care. 2013 ; 15: 21-26
23. Fromont A, Binquet C, Rollot F, et al. Comorbidities at multiple sclerosis diagnosis. J Neurol. 2013 ; 260: 2629-2637
24. Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci. 2000 ; 7: 434-437
25. Hoppenbrouwers IA, Cortes LM, Aulchenko YS, et al. Familial clustering of multiple sclerosis in a Dutch genetic isolate. Mult Scler. 2007 ; 13: 17-24
26. Horton M, Rudick RA, Hara-Cleaver C, et al. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology. 2010 ; 35: 83-90
27. Hussein WI, Reddy SS. Prevalence of diabetes in patients with multiple sclerosis. Diabetes Care. 2006 ; 29: 1984-1985
28. Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler. 2013 ; 19: 1336-1340
29. Kanjwal K, Karabin B, Kanjwal Y, et al. Autonomic dysfunction presenting as postural orthostatic tachycardia syndrome in patients with multiple sclerosis. Int J Med Sci. 2010 ; 7: 62-67
30. Langer-Gould A, Albers K, Van Den Eeden S, et al. Autoimmune diseases prior to the diagnosis of multiple sclerosis: A population-based case-control study. Mult Scler. 2010 ; 16: 855-861
31. Laroni A, Calabrese M, Perini P, et al. Multiple sclerosis and autoimmune diseases: Epidemiology and HLA-DR association in North-east Italy. J Neurol. 2006 ; 253: 636-639
32. Lindegård B.. Diseases associated with multiple sclerosis and epilepsy: A population cohort study of 158,200 middle-aged, urban, native Swedes observed over 10 years (1970-79). Acta Neurol Scand. 1985 ; 71: 267-277
33. Lu E, Zhao Y, Zhu F, et al. Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology. 2013 ; 80: 447-452
34. Marrie RA, Yu B, Leung S, et al. Rising prevalence of vascular comorbidities in MS: Validation of administrative definitions for diabetes, hypertension, hyperlipidemia. Mult Scler. 2012 ; 18: 1310-1319
35. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status, and multiple sclerosis. Mult Scler. 2008 ; 14: 1091-1098
36. Marrosu MG, Cocco E, Lai M, et al. Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: A cohort study. Lancet. 2002 ; 359: 1461-1465
37. Marrosu MG, Motzo C, Murru R, et al. The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. Hum Mol Genet. 2004 ; 13: 2919-2924
38. Midgard R, Grønning M, Riise T, et al. Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand. 1996 ; 93: 322-328
39. Nuyen J, Schellevisa FG, Satarianob WA, et al. Comorbidity was associated with neurologic and psychiatric diseases: A general practice-based controlled study. J Clin Epidemiol. 2006 ; 59: 1274-1284
40. Paz Soldan MM, Pittock SJ, Weigand SD, et al. Statin therapy and multiple sclerosis disability in a population-based cohort. Mult Scler. 2012 ; 18: 358-363
41. Pitzalis M, Zavattari P, Murru R, et al. Genetic loci linked to type 1 diabetes and multiple sclerosis families in Sardinia. BMC Med Genet. 2008 ; 9: 3
42. Ramagopalan SV, Dyment DA, Valdar W, et al. The occurrence of autoimmune disease in Canadian families with multiple sclerosis. Lancet Neurol. 2007 ; 6: 604-610
43. Seyfert S, Klapps P, Meisel C, et al. Multiple sclerosis and other immunologic diseases. Acta Neurol Scand. 1990 ; 81: 37-42
44. Sheu JJ, Lin HC.. Association between multiple sclerosis and chronic periodontitis: A population-based pilot study. Eur J Neurol. 2013 ; 20: 1053-1059
45. Tremlett HL, Evans J, Wiles CM, et al. Asthma and multiple sclerosis: An inverse association in a case-control general practice population. QJM. 2002 ; 95: 753-756
46. Wertman E, Zilber N, Abramsky O. An association between multiple sclerosis and type I diabetes mellitus. J Neurol. 1992 ; 239: 43-45
47. Wynn DR, Rodriguez M, O'Fallon WM, et al. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology. 1990 ; 40: 780-786
48. Palo J, Duchesne J, Wikstrom J. Malignant diseases among patients with multiple sclerosis. J Neurol. 1977 ; 216: 217-222
49. Marrie R, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler. 2015 ; 21 (3). 282-293
50. Marrie RA, Horwitz RI, Cutter G, et al. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011 ; 124: 135-141
51. Sun LM, Lin CL, Chung CJ, et al. Increased breast cancer risk for patients with multiple sclerosis: A nationwide population-based cohort study. Eur J Neurol. 2014 ; 21: 238-244
52. Füvesi J, Bencsik K, Losonczi E, et al. Factors influencing the health-related quality of life in Hungarian multiple sclerosis patients. J Neurol Sci. 2010 ; 293: 59-64
53. Holper L, Coenen M, Weise A, et al. Characterization of functioning in multiple sclerosis using the ICF. J Neurol. 2010 ; 257: 103-113
54. Hopman WM, Coo H, Edgar CM, et al. Factors associated with health-related quality of life in multiple sclerosis. Can J Neurol Sci. 2007 ; 34: 160-166
55. Lix L, Yogendran M, Shaw S, et al. Population-based data sources for chronic disease surveillance. Chronic Dis Can. 2008 ; 29: 22-30
56. Marrie RA, Yu BN, Leung S, et al. Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. Mult Scler Relat Disord. 2013 ; 2: 355-361
57. Krokki O, Bloigu R, Ansakorpi H, et al. Neurological comorbidity and survival in multiple sclerosis. Mult Scler Relat Disord. 2013 ; 3: 72-77
58. Marrie RA, Cutter G, Tyry T. Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. Mult Scler. 2011 ; 17: 1464-1471
59. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: Estimates from monitoring, surveillance, and modelling. Lancet Neurol. 2009 ; 8: 345-354
60. Feigin VL, Lawes CM, Bennett DA, et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: A systematic review. Lancet Neurol. 2009 ; 8: 355-369
61. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: The Global Burden of Disease 2010 Study. Circulation. 2014 ; 129: 1493-1501
62. Levy AR, Tamblyn RM, Fitchett D, et al. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol. 1999 ; 15: 1277-1282
63. Ranadive SM, Yan H, Weikert M, et al. Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc. 2012 ; 44: 238-243
64. Crowson CS, Nicola PJ, Kremers HM, et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?. Arthritis & Rheumatism. 2005 ; 52: 3039-3044
65. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of Myocardial Infarction in Patients With Psoriasis. JAMA. 2006 ; 296: 1735-1741
66. Brinkley DM, Gelfand EV. Valvular heart disease: Classic teaching and emerging paradigms. Am J Med. 2013 ; 126: 1035-1042
67. Lalmohamed A, Bazelier MT, Van Staa TP, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: A population-based cohort study. Eur J Neurol. 2012 ; 19: 1007-1014
68. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet. 2014 ; 383: 2213-2221